Search results
Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). [1] There is some evidence it may improve some ME/CFS symptoms.
Ampligen ® Has Significant Opportunity Across High-Value Multiple Disease Areas ~100,000 IV doses in humans, generally well-tolerated Positive Phase 3 data generated in U.S. in treatment of ME/CFS.
20 lip 2022 · Receiving IRB approval for our Phase 2 study of Ampligen for the treatment of LAPC is the pivotal precursor to the recruitment, enrollment and treatment of patients with locally advanced pancreatic cancer.
4 kwi 2023 · AMP-518 is expected to enroll approximately 80 subjects between the ages of 18 to 60 years across up to 10 centers in the United States. Patients will be randomized 1:1 to receive twice weekly...
14 mar 2012 · Rintatolimod (Ampligen®) used in this study was manufactured in accordance with Good Manufacturing Practice (GMP) and tested under Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) guidelines.
9 lut 2015 · Ampligen (rintatolimod) is an experimental nucleic acid therapeutic in development for the treatment of a variety of chronic diseases and viral disorders. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
25 sty 2024 · AIM ImmunoTech has gained Netherlands Erasmus Medical Center (Erasmus MC) Ethics Committee authorisation to launch a European site for its Phase II clinical trial of Ampligen (rintatolimod) for locally advanced pancreatic cancer.
